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Abstract: 72 
Background: Obesity is caused by an imbalance between energy intake, i.e., eating, and 73 
energy expenditure (EE). Severe obesity is more prevalent in women than men worldwide, 74 
and obesity pathophysiology and the resultant obesity-related disease risks differ in women 75 
and men. The underlying mechanisms are largely unknown. Pre-clinical and clinical research 76 
indicate ovarian hormones may play a major role.   77 
Rationale/Objectives: We systematically reviewed the clinical and pre-clinical literature on the 78 
effects of ovarian hormones on the physiology of adipose tissue (AT) and the regulation of 79 
AT mass by energy intake (i.e., eating) and EE.  80 
Outcomes: We find that estrogens play a leading role in the causes and consequences of 81 
female obesity. With respect to adiposity, estrogens synergize with AT genes to increase 82 
gluteofemoral subcutaneous AT mass and decrease central AT mass in reproductive-age 83 
women, which leads to protective cardiometabolic effects. Loss of estrogens after 84 
menopause, independent of aging, increases total AT and decreases lean body mass, so 85 
that there is little net effect on body weight. Menopause also partially reverses women’s 86 
protective AT distribution. These effects can be counteracted by estrogen treatment. With 87 
respect to eating, increasing estrogen levels progressively decrease eating during the 88 
follicular and peri-ovulatory phases of the menstrual cycle. Progestin levels are associated 89 
with eating during the luteal phase, but there does not appear to be a causal relationship. 90 
Progestins may increase binge-eating and eating stimulated by negative emotional states 91 
during the luteal phase. Pre-clinical research indicates that one mechanism for the pre-92 
ovulatory decrease in eating is a central action of estrogens to increase the satiating potency 93 
of the gastrointestinal hormone cholecystokinin. Another mechanism involves a decrease in 94 
the preference for sweet foods during the follicular phase. Genetic defects in brain α-MSH–95 
MC4R signalling lead to a syndrome of overeating and obesity that is particularly pronounced 96 
in women and in female animals. The syndrome appears around puberty in mice with genetic 97 
deletions of MC4R, suggesting a role of ovarian hormones. Emerging functional brain-98 
imaging data indicate that fluctuations in ovarian hormones affect eating by influencing 99 
 4 
striatal dopaminergic processing of flavour hedonics and lateral prefrontal cortex processing 100 
of cognitive inhibitory controls of eating. There is a dearth of research on the neuroendocrine 101 
control of eating after menopause. There is also comparatively little research on the effects 102 
of ovarian hormones on EE, although changes in ovarian-hormone levels during the 103 
menstrual cycle do affect resting EE.  104 
Wider implications: Women’s markedly greater obesity burden makes understanding the 105 
diverse effects of ovarian hormones on eating, EE and body adiposity urgent research 106 
challenges. A variety of research modalities can be used to investigate these effects in 107 
women, and most of the mechanisms reviewed are accessible in animal models. Therefore, 108 
human and translational research on the roles of ovarian hormones in women’s obesity and 109 
its causes should be intensified to gain further mechanistic insights that may ultimately be 110 
translated into novel anti-obesity therapies and thereby improve women’s health.  111 
 5 
Introduction  112 
That obesity is pandemic is well known (obesity is typically defined as body mass index [BMI, 113 
weight in kg / height in m2]) ≥ 30). In contrast, that sex and gender are important variables in 114 
obesity is less well appreciated. In fact, worldwide, about twice as many women as men 115 
suffer from severe obesity (i.e., grade 2 and 3 obesity, BMI ≥ 35 and 40 kg/m2, respectively) 116 
(Figure 1). Although social factors, especially gender inequality, certainly contribute to male-117 
female differences in obesity prevalence (Kautzky-Willer et al., 2016), the consistent 118 
worldwide disparity in prevalence of severe obesity strongly suggests that biological factors, 119 
i.e., physiological sex differences, also contribute. In support of this, pre-clinical and clinical 120 
studies have revealed women-specific factors in the two physiological determinants of 121 
obesity, the level of energy intake, which is to say eating, and the level of energy expenditure 122 
(EE). Furthermore, this work indicates that ovarian hormones, in particular estrogens, 123 
influence both eating and EE in women. Finally, data also implicate ovarian hormones in the 124 
metabolic function of adipose tissue (AT). In light of these considerations, the goal of this 125 
review is to provide a critical update on the roles of ovarian hormones on the principle 126 
components of obesity, i.e., eating and EE, and on AT physiology.  127 
 128 
Methods   129 
Articles in English indexed in PubMed through January, 2016, were searched using the 130 
following keywords related to: (1) reproductive hormones [estrogen, estradiol, estrone, 131 
estriol, estrogen receptors 1 and 2 (ESR1 and ESR2 in humans, Esr1 and Esr2 in mice and 132 
rats; formerly known as ERα and ERβ, respectively), progesterone, progesterone receptor 133 
(2), androgen, androgen receptors, weight regulation [food intake, adipose tissue, adiposity, 134 
adipocyte, hunger, flavour hedonics, satiation, satiety, EE, physical activity, resting EE 135 
(REE), diet-induced EE, insulin, leptin, inflammation], ghrelin, cholecystokinin (CCK), 136 
glucagon-like peptide 1, peptide YY(3-36)], and (3) central nervous system (CNS) 137 
[neuropeptide Y, melanocortins, dopamine, serotonin, melanocortin receptor, agouti-related 138 
protein, nucleus of the solitary tract (NTS), striatum, putamen, nucleus accumbens, caudate 139 
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nucleus, frontal cortex, functional magnetic-resonance imaging (fMRI)]. Searches were of the 140 
form: body weight OR obesity AND (a reproductive hormone set element) AND (a weight 141 
regulation or CNS set element), where capital letters indicate Boolean connectors. We 142 
sought to identify emerging research foci with clinical translational potential rather than to 143 
provide a comprehensive review.  144 
 145 
AT physiology 146 
Measurement of body adiposity 147 
Anthropomorphic adiposity measures, such as BMI, waist circumference (WC) and waist-hip 148 
ratio (WHR) are simple and inexpensive, but relatively imprecise measures of body adiposity. 149 
Errors are introduced by sex, age, ethnicity, and individual differences in body composition, 150 
such as muscle mass. For example, in one study, BMI misclassified the adiposity of one third 151 
of young adult female athletes (Ode et al., 2007). Furthermore, BMI systematically over-152 
estimates the adiposity of shorter people and under-estimates the adiposity of taller people. 153 
Both BMI and WC are better predictors of total-visceral AT (defined below) than WHR 154 
(Kamel et al., 2000; Koren et al., 2013; Pouliot et al., 1994). In women, WC and WHR 155 
predicts cardiovascular disease better than BMI (Goh et al., 2014). With respect to clinical 156 
practice, however, an expert panel (Klein et al., 2007) concluded that additional 157 
anthropomorphic measures are unlikely to affect clinical management if BMI and standard 158 
cardiometabolic risk factors are considered (Kiernan and Winkleby, 2000). 159 
 160 
Numerous other methods more accurately detect whole-body adiposity. Some, including, air 161 
displacement plethysmography and hydrostatic weighing (Fields et al., 2015; Moon et al., 162 
2011; Silver et al., 2010), are limited in their ability to measure regional AT differences. Dual-163 
energy X-ray absorptiometry (DEXA) can detect regional fat and bone mineral density and 164 
with the aid of a special algorithm can distinguish intra-abdominal and subcutaneous fat 165 
(Kaul et al., 2012), but it does not measure AT volume or distinguish water and other lean-166 
tissue mass (Santen et al., 2010). MRI and computed tomography (CT) are the best 167 
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available methods to measure AT volume and regional distribution in vivo. Whole-body 168 
imaging (i.e., axial images every few cm) is most accurate. Single-level cross-sectional 169 
images are more common, but which abdominal level best estimates central subcutaneous 170 
and total-visceral AT is controversial (Kuk et al., 2006; Shen et al., 2012).  171 
 172 
Histological or plasma assays may soon provide suitably accurate and clinically practical 173 
measures of specific AT depots. For example, Lê et al. (Lê et al., 2011) found that the 174 
degree of macrophage infiltration in subcutaneous AT biopsies predicted total-visceral AT 175 
volume, intrahepatic lipid content and several plasma markers of cardiometabolic-disease 176 
risk. Therefore such methods may provide a safe and cost effective way to measure AT 177 
compartments relevant for health in the future. 178 
 179 
General aspects of AT  180 
Energy is stored for long periods as intracellular droplets of triacylglycerol within adipocytes, 181 
which are mostly organized in discrete AT depots (Rosen and Spiegelman, 2014). 182 
Preadipocytes are pluripotent cells that can differentiate into white or brown adipocytes, 183 
macrophages, muscle and bone progenitors (Tchkonia et al., 2013). The differentiation of 184 
adipocytes from preadipocytes is controlled by insulin-like growth factor, glucocorticoids, and 185 
other growth factors and hormones (Cristancho and Lazar, 2011; Tang and Lane, 2012). 186 
Although the roles of gonadal hormones in this process remain obscure, that estrogens play 187 
an important role is indicated by the effect of estrogenic endocrine disruptors such as 188 
bisphenol to disrupt normal pre-adipocyte differentiation in vitro and by their association with 189 
obesity (Boucher et al., 2014; Ohlstein et al., 2014; Saal et al., 2012). 190 
 191 
The traditional view was that AT is a passive storage depot. AT energy storage is indeed 192 
long term - the half-life of individual triacylglycerol molecules in the subcutaneous AT of 193 
healthy humans is 1.6 years, orders of magnitude more than that of any other energy 194 
metabolite (Arner et al., 2011). Nevertheless, contemporary research clearly indicates, first, 195 
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that AT is a dynamic organ that contributes to metabolic homeostasis in multiple ways, and, 196 
second, that in obesity, AT becomes dysfunctional and contributes to whole-body 197 
pathophysiology and health risk. These pathophysiological processes are mediated both by 198 
free fatty acids (FFA) and other metabolites released by AT and by signalling molecules 199 
secreted by adipocytes, called adipokines, which have local (paracrine) and endocrine 200 
signaling functions (Lee et al., 2013; Tchkonia et al., 2013). Additional signaling molecules 201 
are secreted by AT endothelial cells and AT-resident immune cells.  202 
 203 
A rough categorization of human AT includes five major depots (Shen et al., 2003): (1) 204 
Subcutaneous AT, which can be found from head to foot in obese individuals. Subcutaneous 205 
AT includes superficial and deep sections separated by a fascial plane (Scarpa’s fascia) in 206 
the lower trunk and gluteal femoral areas. As described below, the different components of 207 
subcutaneous AT are separately regulated. (2) Visceral or intraperitoneal AT, which includes 208 
the omental (attached to the stomach), mesenteric (attached to the small intestine) and 209 
epiploic (attached to the large intestine) depots. These depots contain numerous lymph 210 
nodes and are especially prone to infiltration by macrophages during hypertrophy 211 
(Gabrielsson et al., 2003; Lee et al., 2013; Tchkonia et al., 2013). In addition, mesenteric AT 212 
is exposed to absorbed lipids as they drain through the lymphatics. Finally, the vasculature of 213 
visceral AT drains into the hepatic-portal vein, exposing the liver to increased levels of the 214 
FFA, adipokines and immune mediators that it releases. (3) Retroperitoneal and pelvic AT 215 
are separate depots, but are often categorized together with visceral AT because they 216 
cannot be easily distinguished with imaging; we refer to this sum as “total-visceral AT”. (4) 217 
Intra- and extra-pericardial AT. (5) Intramuscular AT, which lies between the muscle 218 
fascicles. Subcutaneous and visceral AT have received the most research and are the focus 219 
of this review. Visceral fat is associated with impaired health while other AT compartments 220 
contribute to a lower degree or may even have a protective effect (Després and Lemieux, 221 
2006).  222 
 223 
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Vague (1947) first noted that, compared with men, women tend to have relatively more 224 
gluteofemoral AT and relatively less centrally located AT, i.e., abdominal subcutaneous and 225 
total-visceral AT. More recent studies confirmed this notion and indicate that these effects 226 
are evident across a wide range of BMI (Gallagher et al., 2005). Nevertheless, there is 227 
substantial individual variation in obesity habitus. Indeed, some obese women have male-228 
typical, central AT distribution (Karpe and Pinnick, 2015).  229 
 230 
Female-typical adiposity  231 
Puberty and young adulthhood 232 
The typical female pattern of regional AT distribution emerges during puberty (Shen et al., 233 
2009; Taylor et al., 2010). In addition, healthy-weight females’ greater absolute AT mass 234 
becomes obvious only after puberty (healthy weight is 18.5 – 24.9 kg/m2). As a result, a 235 
normative young adult woman in the USA (height 1.6 m, BMI 22.5 kg/m2) has ~18 kg body 236 
fat (~30% body weight), of which only ~5% is total visceral AT (Camhi et al., 2011; Gallagher 237 
et al., 1996; Shen et al., 2009), whereas a normative male (height 1.8 m) has ~12 kg body fat 238 
(~15% body weight), of which ~11% is total visceral AT.  239 
 240 
Female-typical AT results from differences among the AT depots in the balance of uptake 241 
and release of FFA (Santosa and Jensen, 2015). FFA uptake and triacylglyceride synthesis 242 
are greater in women’s glutoefemoral than abdominal subcutaneous AT, and lipolysis rates 243 
are lower, thus selectively increasing the relative size of the gluteofemoral depot. These 244 
processes are controlled by complex interactions of genes and ovarian homones that are 245 
only beginning to be understood, for example with recent studies of differential AT gene 246 
expression (Fried et al., 2015; Friedl et al., 2015; Gesta et al., 2006; Karpe and Pinnick, 247 
2015). One study (Karastergiou et al., 2013) found that of 284 genes that were differentially 248 
expressed in gluteofemoral compared with abdominal subcutaneous AT in overweight (mean 249 
BMI, 27 kg/m2) adults, 159 were differentially expressed only in women. Furthermore, many 250 
of the genes were homeobox-family (HOX) genes, which are involved in cell differentiation. 251 
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Thus, a parsimonious hypothesis is that increased levels of estrogens or other reproductive 252 
hormones during puberty differentially activate HOX and other genes to determine regional 253 
AT distribution and physiology. 254 
 255 
Mouse models provide further evidence that abdominal and gluteofemoral subcutaneous 256 
adipocytes differentiate in a sex-dependent, cell-autonomous fashion (Fried et al., 2015). For 257 
example, estrogen receptor 1 (Esr1; formerly known as estrogen receptor-α) was necessary 258 
for establishing the identity of mouse white-adipocyte progenitor cells (Lapid et al., 2014), 259 
and female transgenic mice lacking Esr1 selectively in adipocytes became obese due to 260 
expansion of gonadal AT, whereas additional knock out of Esr2  (formerly estrogen receptor-261 
β) had no effect (Davis et al., 2013). Although this result cannot be translated simply to 262 
humans because humans do not have gonadal AT depots, the similar gene-expression 263 
patterns of mouse gonadal AT and human omental AT (Gesta et al., 2006) encourages the 264 
view that estrogen-ESR1 signalling contributes similarly to the development of human 265 
visceral AT. Finally, when the testes-determining Sry gene was transplanted from the Y 266 
chromosome to an autosome in order to yield XX or XY mice with either male or female 267 
gonads, XX mice had twice as much AT as XY mice independent of gonadal status, 268 
indicating an important contribution of sex-linked genes to the sex difference in total body fat 269 
(Chen et al., 2012). Ongoing research is translating these kinds of data into human AT 270 
physiology (Karastergiou et al., 2013).  271 
 272 
The search for genes mediating the high heritability of human obesity and regional AT 273 
distribution has not yet been successful. The failure of most studies to take into account the 274 
age of onset of obesity, in particular pubertal development, may contribute to this lack of 275 
success. A recent large (n=224,459) genome-wide association study identified 49 single-276 
nucleotide DNA polymorphisms (SNP) related to WHR phenotypes, with 19 expressed more 277 
in women (Shungin et al., 2015). Overall, most SNP were in or near genes expressed by 278 
adipocytes or related to insulin resisitance, suggesting that their analysis might lead to better 279 
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understanding of regional fat distribution and related pathophysiology. None was apparently 280 
related to ESR1, ESR2, androgen receptor or synthesis of estrogens or androgens, which 281 
might be expected to be especially important in the development of obesity during puberty. 282 
Interestingly, however, SNP associated with fat distribution had little overlap with those found 283 
in a similar analysis to be associated with BMI, which were predominately expressed in the 284 
brain (Locke et al., 2015). This suggests that different biological processes underlie the 285 
accumulation and distribution of excess body fat (Fu et al., 2015; Lee and Mattson, 2014). 286 
Moreover, epigenetic regulatory mechanisms, which are not revealed in SNP analyses, are 287 
also involved in the development of obesity (Dalgaard et al., 2016). 288 
 289 
Other methods have revealed some genes apparently involved in the estrogenic regulation of 290 
total adiposity. A study of SNP rs7757956 in intron 4 of ESR1 indicated that an activational 291 
effect of estrogen signalling via ESR1 influences the development of obesity in pubertal girls 292 
(Tobias et al., 2007). Girls, but not boys, on average 12 year-old, who were in Tanner stages 293 
3-5 and bore a TT genotype at rs7757956 had 9% more body fat, as measured by DEXA, 294 
than TA- or AA-genotype girls. They also had 18% more height-adjusted body fat than TT-295 
genotype girls in Tanner stages 1-2. As the TT genotype is common (75%), this may be an 296 
important contributor to female obesity. The influence of this SNP at later ages remains to be 297 
investigated. 298 
 299 
Studies of hormonal contraception fail to reveal significant effects on body weight, Gallo et al. 300 
(2014) screened 734 English-language reports of effects of combination oral hormonal 301 
contraceptives or combination skin patches on body weight in healthy reproductive-age 302 
women and found 49 that met their quality criteria (inclusion of at least three cycles, inclusion 303 
of effect means and variabilities, etc.). These failed to show any consistent effect of 304 
combination contracptive use or its discontinuation on body weight, although the amount and 305 
quality of data were not judged to be of the highest quality. For example, only four studies 306 
included placebo-treated or no-intervention groups. A similar review of the effects of 307 
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progestin-only contraceptives on body weight identified only 15 studies, most of moderate to 308 
low quality (Lopez et al., 2013). Twelve of these failed to detect weight changes, but in three 309 
there were weight gains of about 2 kg/y. Percent body AT was also increased in two studies 310 
in which body composition was measured. Thus, progestin-only contraception may slightly 311 
increase body weight and adipoisty, but available evidence does not establish this 312 
unambiguously.  313 
 314 
Gonadotropin-releasing hormone (GnRH) agonists are often used to treat early or precocious 315 
puberty. Studies of the effect of GnRH-agonist treatment on weight gain are mixed, with 316 
some studies suggesting a small increase (Aguiar et al., 2006; Wolters et al., 2012), some a 317 
decrease (van der Sluis et al., 2002), and others no effect (Głab et al., 2009; Ko et al., 2011). 318 
Interestingly, weight increase seems to occur only in girls who are healthy when initiating 319 
treatment, but not in girls who are overweight (Wolters et al., 2012). GnRH agonists are also 320 
used in the treatment of endometriosis, but this is rarely done for more than six months in 321 
adult women due to deleterious effects on bone metabolism. Unfortunately, to our knowledge 322 
none of the studies investigating the use of GnRH agonists in women with endometriosis has 323 
described effects on body weight. 324 
 325 
Menopause and hormone therapy (HT) 326 
Aging per se increases adiposity, which complicates the estimation of the effects of 327 
menopause. Age and menopause are best segregated with multiple regression or similar 328 
statistical analyses, and therefore we consider only such studies. Table 1 shows data from 329 
five such cross-sectional studies, four in which DEXA was used to estimate whole-body lean 330 
and fat masses (Ley et al., 1992; Panotopoulos et al., 1996; Svendsen et al., 1995; 331 
Trémollieres et al., 1996) and one in which whole-body MRI was used (Phillips et al., 2008). 332 
Strikingly, these studies indicate that in both healthy-weight and mildly obese women, 333 
menopause increases body fat by ~5% of body weight and decreases fat-free body mass by 334 
a slightly smaller amount. These opposing changes explain why menopause has no marked 335 
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effect on body weight or BMI in most studies. The obvious clinical implication of these data is 336 
that women should be advised to lose several kg body fat during the menopausal transition 337 
in order to maintain cardiometabolic health.  338 
 339 
Menopause appears to preferentially increase total-visceral AT, although the magnitude of 340 
the effect is uncertain. In two studies (Franklin et al., 2009; Kanaley et al., 2001) in which 341 
several axial MRI scans were made between the head of the femur and the kidneys in white 342 
US American women, both abdominal subcutaneous and total-visceral AT increased after 343 
menopause, with a slightly greater relative increase in total-visceral AT. In another MRI study 344 
(Phillips et al., 2008), however, the relative increase in total-visceral AT was twice that of 345 
total AT. Several studies using DEXA confimed a correlation between postmenopausal 346 
status and increased total-visceral AT (Gambacciani et al., 1999; Lovejoy et al., 2008; 347 
Svendsen et al., 1995; Trémollieres et al., 1996). Even in non-obese women significant 348 
increases in total-visceral fat (Abdulnour et al., 2012) and percent body lipid (Ho et al., 2010) 349 
occurred during the menopausal transition. Moreover, in BMI matched (~25 kg/m2) pre- and 350 
postmenopausal women, percent visceral AT was significantly lower in the premenopausal 351 
group, whereas no association of age and total-visceral AT was detected (Kanaley et al., 352 
2001). 353 
 354 
We are not aware of imaging studies on the effects of surgical menopause by ovariectomy, 355 
on AT. Although results have to be interpreted with caution due to methodological limitations, 356 
such as lack of control for the indications for surgery or for hysterectomy vs. ovariectomy, 357 
available data support an association between surgical menopause and increased weight 358 
gain (Matthews et al., 2001; Sowers et al., 1996; Tom et al., 2012), in line with the 359 
importance of ovarian hormones for obesity. 360 
 361 
In younger post-menopausal women (age 50-59 y), estrogenic HT reduces fat mass, 362 
improves bone-mineral density, appears to preserve fat-free mass (FFM), reduces the risk of 363 
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type-2 diabetes mellitus, retards atherosclerosis, and reduces all-cause mortality (Manson 364 
and Kaunitz, 2016; Manson et al., 2013; Santen et al., 2010). At least in the case of 365 
atherosclerosis, benefits occur only if estrogenic HT is begun within less than ~ 6 y of 366 
menopause (Hodis et al., 2016). In addition, estradiol treatment, but not progestin or 367 
testosterone treatment, lowered plasma very low-density lipoptrotein-triglyceride 368 
concentration ~ 30% in healthy postmenopausal women by increasing their plasma clearance 369 
(Smith et al., 2014).   370 
 371 
Santen and colleagues reviewed 13 placebo-controlled DEXA or CT studies studies in which 372 
unopposed estrogen HT or estrogen plus progestin HT reduced body fat. HT with progestins 373 
alone increased adiposity (Clark et al., 2005; Dal'Ava et al., 2014) indicating that the effects 374 
of HT on adiposity loss are purely estrogenic. Santen et al. (Santen et al., 2010) also 375 
reviewed eight studies in which estrogenic HT reduced the tendency of postmenopausal 376 
women to develop more central obesity, versus two in which this was not the case, 377 
consistent with the data reviewed above indicating that estrogens contribute to the 378 
determination of regional adiposity distribution. 379 
  380 
That estrogen levels are higher in non-obese than obese premenopausal women also 381 
supports a role of estrogens in restraining AT. Age-corrected early-follicular estradiol levels 382 
were 40 pg/mL in healthy-weight women vs. 33 pg/mL in obese women, with no overlap in 383 
95% confidence intervals (95% CI) (Freeman et al., 2010). In contrast, after menopause 384 
estradiol levels were lower overall, although higher in obese than non-obese women (21 vs. 385 
12 pg/mL, no overlap in 95% CI). After menopause, estradiol originates mainly in the AT and 386 
appears to have no endocrine function.  387 
It is important to emphasize that as a result of the opposite effects of HT on adiposity and 388 
FFM, HT leads to little or no change in total body weight. According to a Cochrane meta-389 
analysis (Norman et al., 2000) unopposed estrogen treatment had no significant effect on 390 
total weight (9 randomized controlled trials [RCT], mean difference vs. no HT, 0.0 kg, 95% CI 391 
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-0.6 - 0.7 kg) or BMI (2 RCT, mean difference -0.1 kg, 95% CI -0.4 - 0.1 kg); similarly, 392 
estrogen plus progestin treatment had no significant effect on weight (10 RCT, mean 393 
difference, 0.0 kg, 95% CI -0.4 - 0.5 kg) or BMI (10 RCT, mean difference -0.1 kg,  CI -0.3 - 394 
0.1 kg). Thus, women’s fear that estrogenic HT leads to weight gain (Légaré et al., 2000) is 395 
unfounded. Rather, the likelihood of benificial changes in body composition and metabolic 396 
health with estrogenic HT should be considered by women deciding on postmenopausal HT. 397 
 398 
Obesity pathophysiology 399 
Simple Obesity 400 
Obesity causes progressive cardiometabolic dysfunction (Lumeng et al., 2007; Mauvais-401 
Jarvis et al., 2013; Tchkonia et al., 2013). Expanded AT depots release more FFA, which 402 
increase insulin secretion, decrease insulin sensitivity, and increase hepatic production of 403 
very low-density lipoproteins. In addition, hypertrophic adipocytes attract macrophages into 404 
the AT, which induces a sterile inflammation-like state characterized by secretion of 405 
numerous proinflammatory cytokines and adipokines. Finally, AT vasculature often fails to 406 
expand sufficiently in obesity, leading to local hypoxia that exacerbates the inflammatory 407 
state (Pasarica et al., 2009; Sun et al., 2013).  408 
 409 
These processes are influenced importantly by ovarian hormones. For example, in rats, 410 
ovariectomy increases immune-cell infilatration into the AT and increases insulin resistance 411 
even if adiposity is controlled (Rogers et al., 2009; Vieira Potter et al., 2012). Increases in 412 
circulating adipokines and immune factors in postmenopausal women suggest similar effects 413 
contribute to increased risk of cardiometabolic diease in these women (Pfeilschifter et al., 414 
2002; Polotsky and Polotsky, 2010). Conversely, in younger women, HT reduces or delays 415 
these pathological processes (Manson and Kaunitz, 2016; Manson et al., 2013; Santen et al., 416 
2010). Thus, studies of the roles of estrogens is an emerging theme in obesity-related 417 
cardiometabolic disease (Blenck et al., 2016; DeClercq et al., 2008; Monteiro et al., 2014).  418 
 419 
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An additional potential mechanism through which estrogens improve AT function is related to 420 
the “browning” of white adipocytes (Palmer and Clegg, 2015), i.e., increased expression of 421 
uncoupling protein-1 (UCP-1), which generates heat without synthesizing ATP, thus 422 
increasing EE, and reduces cardiometabolic risk (Rosen and Spiegelman, 2014). Estrogens 423 
may induce browning in two ways. First, estrogens act in the heart to increase the secretion 424 
of cardiac natriuretic peptides (Jankowski et al., 2001; Wang et al., 2002), which in turn act in 425 
the AT to increase browning (Collins, 2014). Second, estrogens may increase hypothalamic 426 
expression of brain-derived neurotrophic factor, which increases sympathetic outflow to the 427 
AT and increases browning (Cao et al., 2011; Palmer and Clegg, 2015). 428 
 429 
Different AT depots are differentially predisposed to obesity-related pathophysiology (Fried et 430 
al., 2015; Karpe and Pinnick, 2015; Lee et al., 2013; Tchkonia et al., 2013) (Figure 2). 431 
Centrally located AT, especially visceral AT, brings the greatest health risk (Després and 432 
Lemieux, 2006; Pischon et al., 2008; Wang et al., 2005). A variety of data indicate that this is 433 
related to the direct delivery of FFA and proinflammatory immune mediators to the liver 434 
(Bergman et al., 2006; Item and Konrad, 2012; Rytka et al., 2011). Indeed, omental AT 435 
resection added further metabolic benefits to Roux-en-Y gastric bypass surgery (Dillard et 436 
al., 2013). Mesenteric AT appears to be even more toxic, as in comparison to subcutaneous 437 
or omental AT, it is more densely innervated by sympathetic efferents, expresses more 438 
glucocorticoid receptors, and is more prone to macrophage migration (Tchkonia et al., 2013). 439 
Abdominal subcutaneous AT also has adverse metabolic characteristics (Tchkonia et al., 440 
2013), especially deep subcutaneous AT (Koster et al., 2010; Smith et al., 2001). 441 
 442 
In contrast to all other AT depots, gluteofemoral superficial subcutaneous AT actually 443 
reduces cardiometabolic-disease risk (Koster et al., 2010; Lee et al., 2013; Snijder et al., 444 
2004; Yusuf et al., 2005). Indeed, women with marked gluteofemoral obesity often remain 445 
metabolically healthy (Karpe and Pinnick, 2015). Many factors appear to contribute to the 446 
development of larger gluteofemoral subcutaneous AT depots in women and to this depot’s 447 
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protective nature (Karpe and Pinnick, 2015; Lee et al., 2013; Santosa et al., 2008; Tchkonia 448 
et al., 2013). Gluteofemoral subcutaneous AT releases more of the insulin-sensitizing 449 
adipokine palmitoleate than abdominal subcutaneous AT (Pinnick et al., 2012). Adipocytes in 450 
gluteofemoral subcutaneous AT also have greater lipoprotein-lipase activity in women than 451 
men, indicating that they more effectively clear triacylglyceride after meals (Votruba and 452 
Jensen, 2007). Moreover, uptake of plasma FFA, lipogenesis and triacylglycerol re-453 
esterification are greater in women’s gluteofemoral subcutaneous AT than in their abdominal 454 
subcutaneous AT, whereas the opposite is true in men (Koutsari et al., 2011; Søndergaard et 455 
al., 2012). Together, these characteristics of women’s gluteofemoral subcutaneous AT 456 
contribute to the greater size of this depot, the greater stability of stored triacylglycerol, and 457 
the lower plasma FFA levels.  458 
 459 
Another factor relevant to sex differences in AT function is the greater proliferative potential 460 
of preadipocytes in subcutaneous vs. visceral AT. For example, Tchoukalova and colleagues 461 
(Tchoukalova et al., 2010) overfed healthy-weight men and women (mean BMI, 22.1 kg/m2) 462 
for eight weeks, leading to a gain of 3.8 kg fat mass and an increase in mean BMI to 23.6 463 
kg/m2. Strikingly, women displayed greater AT hyperplasia, so that their average adipocyte 464 
size decreased with weight gain. This was most evident in the femoral fat, and was 465 
associated with relatively greater expansion of gluteofemoral than central AT. In addition, 466 
women with larger baseline abdominal subcutaneous adipocytes also displayed marked 467 
hyperplasia in that depot. This suggests that as AT expands in obesity, the larger number of 468 
gluteofemoral adipocytes in women permits them to store more triacylglycerol before 469 
reaching dysfunctional degrees of hypertrophy (Tchkonia et al., 2013). Unfortunately, the 470 
specific effects of ovarian hormones on adipose-tissue cell biology have not yet been 471 
intensively researched. This is a major challenge facing women’s health research.  472 
 473 
  474 
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Polycsytic Ovary Syndrome (PCOS) 475 
PCOS is characterized by hyperandrogenism, chronic anovulation and polycystic ovaries 476 
(Dumesic et al., 2015; McCartney and Marshall, 2016). One of the primary pathological 477 
changes thought to lead to PCOS is increased ovarian androgen secretion. Indeed, 478 
increased androgen production occurs even in theca cells cultured from women with PCOS 479 
(Nelson et al., 1999). This pathology may be caused in some women by polymorphisms of 480 
DENND1A, which encodes a protein affecting the placement of cell-surface receptors 481 
(McAllister et al., 2014).  482 
 483 
Although the prevalence of PCOS is similar in healthy-weight, overweight and obese women 484 
(Yildiz et al., 2008), about 40-50% of PCOS patients are obese (Carmina et al., 2009; Teede 485 
et al., 2010). Some studies suggest that PCOS is associated with greater abdominal obesity 486 
(e.g., (Carmina et al., 2007), but this is controversial (Barber et al., 2008). Although obesity 487 
pathophysiology related to PCOS is poorly understood, several results support key roles of 488 
increased estrogen and androgen secretion. Androgens can lead to dyslipidemia indirectly by 489 
exacerbating insulin resistance, leading to altered lipid metabolism and body composition, 490 
and directly, through effects in the AT (Diamanti-Kandarakis, 2007). Whether AT dysfunction 491 
is primary or secondary to hyperandrogenism or other abnormalities in PCOS, however, 492 
remains unknown (Villa and Pratley, 2011). Women with PCOS have lower lipoprotein lipase 493 
(LPL) expression in subcutaneous AT than healthy women (Mannerås-Holm et al., 2014). 494 
Both androgens and estrogens inhibit AT LPL activity (Blouin et al., 2010; Pedersen et al., 495 
2004), and even after controlling for BMI, expression of LPL in the subcutaneous AT 496 
correlated negatively with plasma estradiol (Mannerås-Holm et al., 2014). Excessive visceral 497 
fat distribution (Diamanti-Kandarakis, 2007; Escobar-Morreale and San Millán, 2007) and 498 
disturbed adipokine release seems to influence PCOS development (Torres-Leal et al., 2010; 499 
Villa and Pratley, 2011). For example, in women with PCOS, leptin expression was reduced 500 
in the subcutaneous AT, adiponectin expression was reduced in both subcutaneous and 501 
omental AT, and adiponectin receptor-2 expression was reduced in subcutaneous AT 502 
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(Carmina et al., 2008; Mannerås-Holm et al., 2014). These and other adipokines may 503 
modulate the hypothalamic-pituitary-gonadal axis through receptors in pituitary FSH, LH and 504 
TSH cells (Psilopanagioti et al., 2009; Sone et al., 2001; Taheri et al., 2002) so as to 505 
increase ovarian hormone secretion in patients with PCOS (Olszanecka-Glinianowicz et al., 506 
2011; 2013). Additionally, some adipokines may directly influence ovarian steroidogenesis 507 
(Tersigni et al., 2011). Consistent with a link between decreased adipokines and increased 508 
ovarian hormone secretion, plasma estradiol levels were negatively correlated with 509 
adiponectin receptor-1 in the subcutaneous AT of women with PCOS independent of BMI; 510 
testosterone levels, however, were not significantly correlated with adiponectin receptor-1 511 
(Mannerås-Holm et al., 2014). Interestingly, although AT inflammation was not different in 512 
women with PCOS and BMI-matched control women (Lindholm et al., 2011), adiponectin 513 
release in response to the proinflammatory cytokine tumour necrosis factor-α was decreased 514 
in adipocyte obtained from overweight or obese women with PCOS  (Chazenbalk et al., 515 
2010).    516 
 517 
EATING  518 
General aspects of the control of eating 519 
The intake of metabolic energy occurs mainly in the form of meals (including snacks). Meals 520 
and the surrounding affective and cognitive processes are the products of a widely 521 
distributed information-processing network in the brain, described below, that produces 522 
conscious and unconscious responses that underlie planning to obtain food, motivational 523 
urges to eat, planning to obtain food, eating per se, the pleasurable, or hedonic, aspects of 524 
eating, satiation, and the effects of nutrient repletion on learning. 525 
 526 
The primary internal stimuli controlling eating include the subjective value assigned to food 527 
and neural and endocrine feedbacks from the gastrointestinal (GI) tract, from AT, and from 528 
metabolic processes. “Food value” in this context refers to reinforcement, i.e., the ability of 529 
food stimuli to support learning, to generate approach behaviour, and to elicit emotional 530 
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responses, including flavour hedonics (Schultz, 2015). Beyond these, there are several 531 
secondary or modulatory internal factors, ranging from circadian rhythm to psychological 532 
factors and motivators such as stress, emotional state, cognitive control, etc. As reviewed 533 
below, reproductive hormones importantly modulate these physiological controls of eating 534 
(Asarian and Geary, 2013; López and Tena-Sempere, 2015; Mauvais-Jarvis et al., 2013). 535 
External stimuli, in particular stimuli with learned cognitive and affective meanings, also play 536 
important modulatory roles in eating (French et al., 2012; Higgs et al., 2012). There is a 537 
dearth of research on the influence of reproductive hormones on these controls of eating. 538 
This is unfortunate because, for example, estrogens and their lack after menopause can 539 
influence affective (Joffe et al., 2011; Schmidt et al., 2015) and cognitive (Hara et al., 2015) 540 
functions in women.     541 
 542 
Roles of ovarian hormones   543 
The best-established effect of ovarian hormones on eating is the progressive decrease in 544 
eating during the follicular phase of the menstrual cycle. In healthy-weight cycling women, 545 
food intake decreases ~200-300 kcal/d from the luteal maximum to the peri-ovulatory 546 
minimum (Figure 3), an amount relevant to body-weight regulation (Asarian and Geary, 547 
2013; Hall et al., 2011). Available data indicate that eating does not decrease during 548 
anovulatory cycles (Barr et al., 1995; Rock et al., 1996), that the decrease in ovulatory cycles 549 
is due to decreased meal size rather than decreased meal frequency (Brennan et al., 2009; 550 
Pohle-Krauza et al., 2008) and related to a decrease in the intake of sweet foods (Bowen 551 
and Grunberg, 1990; Fong and Kretsch, 1993), Old-world monkeys and apes (Parvorder 552 
Catarrhini), which have ovarian cycles similar to those of women (Zeleznic and Pohl, 2006), 553 
as well as mice, rats and many other species display comparable cyclic decreases in meal 554 
size and food intake. Loss of estrogens after ovariectomy increases meal size, food intake 555 
and body weight in old-world monkeys, rats and mice (Asarian and Geary, 2013; Bellino and 556 
Wise, 2003; Sullivan et al., 2005), suggesting that increased eating contributes to the 557 
increase in AT after menopause in women, but whether this is so is unknown. 558 
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Experiments in rats and mice indicate that estrogens signalling via Esr1 receptors mediate 559 
cyclic change in eating in those species, which appear to correspond to the decrease in 560 
eating during the human follicular and peri-ovulatory phases (Asarian and Geary, 2013). Rats 561 
and mice do not have luteal phases, however, and the control of eating in this phase of the 562 
menstrual cycle is less well understood. Although it is reasonable to hypothesize that 563 
progestins oppose the inhibitory effects of estrogens during the luteal phase, data fail to 564 
support this. Physiological doses of estradiol inhibited eating in ovariectomizued rhesus 565 
macaques, and this was not affected by progesterone treatment (Czaja, 1978). Similarly, 566 
estrogen together with escalating progestin doses failed to affect eating women (Eck et al., 567 
1997), although the experiment was limited because the participants were cycling, so that the 568 
treatment effects may have been obscured by the effects of endogenous hormones, and 569 
because diet records, rather than measure of actual eating, were used. In addition, depot 570 
medroxyprogesterone failed to affect food intake in an adequately powered, prospective, 571 
placebo-controlled study in cycling women (Pelkman et al., 2001).  572 
 573 
Binge eating, referring to eating an abnormally large amount of food on a single occasion 574 
with a feeling of loss of control over eating, is a dysregulated form of eating especially 575 
prevalent in girls and women (Hilbert et al., 2012; Reichborn-Kjennerud et al., 2003). Binge 576 
eating is prodromal to bulimia nervosa, binge-eating disorder, and obesity.  It is also highly 577 
heritable (Davis, 2015). Female rats are much more prone than male rats to develop binge-578 
like eating (Klump et al., 2013). Related to binge eating is emotional eating, i.e., eating in 579 
response to negative emotions, and this is also more prevalent in girls and women.  580 
 581 
Binge eating develops most often during puberty, in association with higher estrogen levels 582 
(Klump et al., 2010). In addition, binge and emotional eating vary through the menstrual 583 
cycle, with lower rates in the late-luteal through the peri-ovulatory phases and higher rates 584 
during the mid-luteal phase (Culbert et al., 2016). A time-series analysis of binge tendencies 585 
and ovarian hormone levels through the cycle suggested that estrogens inhibit emotional and 586 
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binge eating and progestins oppose this effect of estrogens, i.e., indirectly stimulate 587 
emotional and binge eating (Klump et al., 2014). This is the strongest indication that 588 
progestins are clinically important in dysregulated eating in human females. Estradiol, but not 589 
progesterone, reduced amount eaten during binge-like episodes in rats (Yu et al., 2011), but 590 
whether this is a useful model of binge size or frequency in women is not known.  591 
 592 
Peripheral mechanisms 593 
Taste. Although the perception of sweet and creaminess differs in men and women 594 
(Bartoshuk et al., 1994; Hayes and Duffy, 2008) and women’s intake of sweet food increases 595 
during the luteal phase (Bowen and Grunberg, 1990) and during pregnancy (Belzer et al., 596 
2010), the roles of ovarian hormones in these phenomena have not been carefully 597 
investigated (Asarian and Geary, 2013).  598 
 599 
GI signals. A variety of GI neural and endocrine signals are candidate meal-control 600 
mechanisms (Asarian and Geary, 2013; Camilleri, 2015). Unfortunately, research on their 601 
operation in women remains sparse. Ghrelin, a hormone secreted by the stomach, stimulates 602 
meal initiation and increases meal size. In rats, there was an estradiol-dependent increase in 603 
ghrelin’s eating-stimulatory effect during the first two days of the four-day ovarian cycle 604 
(ovulation occurs on the last night), and ghrelin levels increased after ovariectomy in parallel 605 
to the increase in eating (Clegg et al., 2007). The small-intestinal hormone cholecystokinin 606 
(CCK) reduces meal size by hastening meal termination, i.e., by producing satiation. CCK is 607 
the only endocrine meal-control signal that can be considered to have a proven normal or 608 
“physiological” role in humans. That is, intravenous infusion of CCK in amounts that mimic 609 
prandial changes in plasma levels is sufficient to reduce meal size, CCK-receptor 610 
antagonists reduce the satiating potency of intraduodenal fat infusions, and CCK-receptor 611 
antagonists administered alone increase meal size (Geary and Moran, 2016). In rats, 612 
estrogens act via Esr1 in the hindbrain to increase CCK’s satiating action (see below).  613 
Unfortunately, whether estrogens affect CCK satiation in women is unknown. The intestinal 614 
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hormones glucagon-like peptide-1 (GLP-1) and peptide YY(3-36) are also candidate eating-615 
inhibitory signals, and estradiol increases GLP-1 satiating action in ovariectomized rats 616 
(Asarian and Geary, 2013).  617 
 618 
Leptin. Endocrine signals related to AT mass, notably leptin and insulin, contribute to the 619 
control of eating (Le Foll et al., 2014; Levin et al., 2011). Leptin is secreted by white 620 
adipocytes, and basal (fasting) plasma leptin levels are highly correlated with AT mass. 621 
Interestingly, for a given level of fat mass, leptin levels are higher in women than men, and 622 
this difference decreases after menopause. Estrogen levels and differences in intra-623 
abdominal and subcutaneous AT distribution contribute to these effects (Rosenbaum and 624 
Leibel, 1999; Rosenbaum et al., 2001). Originally hypothesized to be the crucial link between 625 
body adiposity and the controls of eating and EE, leptin is now considered to defend only 626 
against reductions in body weight, not against weight increases (Ravussin et al., 2014). 627 
Whether estrogens interact with leptin to control eating is controversial. In ovariectomized 628 
rats, estradiol increased the eating-inhibitory potency of acute leptin injections (Clegg et al., 629 
2003), but not that of chronic leptin treatment (Chen and Heiman, 2001). Furthermore, food 630 
intake was not correlated to plasma leptin levels in cycling women (Paolisso et al., 1999). 631 
None of these studies, however, was done in the weight-reduced state when leptin’s 632 
contribution to eating is greatest.  633 
 634 
The brain mechanisms mediating potential interactive effects of leptin and estrogens on 635 
eating are also uncertain. In mice and rats, Esr1 is expressed in about 10% of neurons that 636 
express the signaling leptin receptor (Leprb) in the arcuate nucleus of the hypothalamus 637 
(ARC), the caudal medial nucleus of the solitary tract (cmNTS) in the brainstem, and several 638 
other areas thought to mediate the control of eating (Asarian, unpublished data; (Kim et al., 639 
2016)). Esr1/Leprb co-expression is much higher, ∼80%, in the preoptic area (Kim et al., 640 
2016), one of the brain sites containing the GnRH neurons that control FSH and LH secretion 641 
(Herbison, 2006). Kim and colleagues (Kim et al., 2016) reported that although food intake 642 
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was increased in transgenic mice lacking Esr1 in Leprb neurons globally, estradiol treatment 643 
did not activate Leprb neurons in the ARC of ovariectomized mice, suggesting that estrogens 644 
and leptin do not affect ARC Esr1/Leprb neurons to inhibit eating. In contrast, Asarian 645 
(unpublished data) found that knockdown of Leprb neurons in the mNTS with RNA-646 
interference increased eating and completely prevented estradiol from inhibiting food intake 647 
in ovariectomized rats, suggestng an Esr1/Leprb interaction in the mNTS is necessary for the 648 
normal control of eating.  649 
 650 
Insulin. Basal plasma levels of insulin also correlate with body fat mass, and insulin may act 651 
in the brain to control eating and EE. Estrogens appear to regulate the effects of insulin on 652 
eating. Central administration of insulin inhibited eating more ovariectomized than in intact 653 
rats, and this was reversed by central estradiol administration (Clegg et al., 2006). These 654 
effects do not occur in peripubertal rats (Keen-Rhinehart et al., 2009), further suggesting an 655 
activational role of estradiol. Interestingly, female, but not male, transgenic mice with brain-656 
specific null mutations of the insulin receptor are hyperphagic, which in females was related 657 
to profound reductions of LH and signs of defective ovarian follicle maturation, indicating a 658 
role for neural insulin receptors in the normal function of the hypothalamic-pituitary-gonadal 659 
axis (Brüning et al., 2000).  660 
 661 
Intra-nasal insulin delivery has been used to selectively stimulate brain insulin receptors in 662 
humans. Similar to the rat studies, intra-nasal insulin before meals decreased eating more in 663 
men than in reproductive-age women (Benedict et al., 2008). In apparent contast to the 664 
findings of Clegg and colleagues (Clegg et al., 2006) in rats described above, premeal intra-665 
nasal insulin failed to inhibit eating in post-menopausal women (Krug et al., 2010). In 666 
contrast, intra-nasal insulin given after meals reduced subsequent intake of preferred snack 667 
foods in young women taking high-estrogen contraceptives, suggesting that insulin increases 668 
postprandial satiety in women (Hallschmid et al., 2012). These data suggest that central 669 
insulin-based pharmacotherapy might be an effective obesity treatment in women.  670 
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Central mechanisms 671 
A widely distributed central neural network controls eating (Berthoud, 2002; Castro and 672 
Berridge, 2014; Farr et al., 2016;  Geary and Moran, 2016; Grill and Hayes, 2012; Schultz, 673 
2015; Shin et al., 2009; Val-Laillet et al., 2015). Local circuits in the caudal brainstem 674 
integrate a variety of sensory inputs, including gustatory, vagal afferent, spinal visceral 675 
afferent, and many GI-hormone signals, and also produce the consummatory behaviors of 676 
eating. Animal studies indicate that the hypothalamus plays the leading role in homeostatic 677 
eating, i.e., eating stimulated by nutrient depletion. Additional cerebral regions involved in 678 
eating include primary and secondary gustatory regions (insula and orbitofrontal cortex) as 679 
well as regions involved in memory (hippocampus) and cognitive control (dorsolateral 680 
prefrontal cortex, inferior frontal cortex, and cingulate cortex). Neuropharmacological and 681 
molecular genetic studies in animals and fMRI studies in humans indicate that the striatum 682 
(which consists of the nucleus accumbens, caudate nucleus and putamen), the orbitofrontal 683 
cortex, the amygdala, and the midbrain dopamine neurons perform neural computation of the 684 
subjective value of food stimuli (“value” was defined above). Estrogens and other gonadal 685 
steroids diffuse freely through the blood-brain barrier (Pardridge et al., 1980), act on cognate 686 
receptors in several of these areas, and through them affect eating-related neural information 687 
processing in these areas and in areas linked to them via neural projections (López and 688 
Tena-Sempere, 2015) (Figure 4).  689 
 690 
Studies in rats indicate that estrogen-Esr1 signalling in neurons in the cmNTS in the caudal 691 
brainstem controls the estrogenic inhibition of normal eating (Asarian and Geary, 2013). That 692 
is, knockdown of cmNTS Esr1 with RNA interference increased eating and body weight and 693 
completely blocked the usual eating-inhibitory effect of estradiol in ovariectomized rats. No 694 
other brain site has been similarly linked to the estrogenic control of eating (e.g., ARC data 695 
were discussed in the leptin sections) (Asarian and Geary, 2013). The network effects of 696 
cmNTS estrogen stimulation, of course, may involve the hypothalamus and other forebrain 697 
sites. For example, expression of the neurotransmitter agouti-related protein (AgRP) in 698 
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neurons in the ARC changes across the ovarian cycle in mice, and transgenic lesions of 699 
AgRP neurons prevented the cyclic decrease in eating; these neurons do not express Esr1, 700 
however, indicating that these effects are functionally downstream of estrogens’ neural 701 
actions (Olofsson et al., 2009).  702 
 703 
AgRP neurons appear to be selectively involved in the aversive, homeostatic hunger 704 
produced by prolonged food deprivation, in contrast to the incentive-state like hunger that is 705 
more operative in spontaneous eating (Betley et al., 2015). AgRP neurons secrete the 706 
neurotransmitters NPY and glutamate as well as AgRP, and these molecules appear to have 707 
temporally distinct contributions to hunger (Krashes et al., 2013). Unfortunately, the roles of 708 
ovarian hormones in these effects have not yet been tested. It is important to note in this 709 
regard that specific aspects of eating are likely to involve Esr in different sites. For example, 710 
binge-like eating in mice apparently depends on estrogen-Esr1 signaling in serotoninergic 711 
neurons in the dorsal raphe nuclei (Cao et al., 2014). This is especially interesting because 712 
women with bulimia nervosa had reduced serotonin-transporter binding in the dorsal raphe 713 
both during active bulimia nervosa and after recovery (Pichika et al., 2012).  714 
 715 
Pro-opiomelanocortin neurons, which release the neurotransmitters α-melanocycte-716 
stimulating hormone and β-endorphin, also may be involved in the estrogenic inhibition of 717 
eating. Brain α-melanocycte-stimulating hormone neurons signal mainly via melanocortin-3 718 
receptors in the ARC and melanocortin-4 receptors (MC4R) in the paraventricular nucleus of 719 
the hypothalamus (Biebermann et al., 2012), and loss-of-function polymorphisms of human 720 
MC4R lead to voracious appetite and obesity (Dempfle et al., 2004; Stutzmann et al., 2008; 721 
Valette et al., 2013). MC4R defects have a prevalence of ฀2-5% in obese Europeans, 722 
making it one of the commonest of all genetic diseases (O'Rahilly and Farooqi, 2006; Tao, 723 
2010). Importantly, weight gain is about twice as much in women as in men, ฀8-9 kg/m2 vs 724 
฀4-5 kg/m2. Mice with null mutations of this gene (Mc4r-/- mice) show a similar syndrome, 725 
again with a marked sex difference that begins around puberty, suggestive of activational 726 
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effects of reproductive hormones (Huszar et al., 1997). In contrast, obesity was already 727 
present in pre-pubertal boys and girls with either of two MC4R polymorphisms (Vogel et al., 728 
2011). Separate analyses of just one of these, SNP rs17782313, however, unveiled a 729 
pronounced sex difference. In women bearing this SNP, but not in men, there were increases 730 
in the eating traits disinhibition and emotional eating as well as differences in gray-matter 731 
volume in the eating-related areas including the right amygdala, right hippocampus, and 732 
medial orbitofrontal cortex (Horstmann et al., 2013). The effects of estrogens on POMC 733 
neurons may be mediated by both Esr1 (Xu et al., 2011) and the recently discovered Gq-734 
coupled membrane estrogen receptor (Smith et al., 2013). Whether estrogens act directly on 735 
POMC neurons or indirectly and the sites involved, however, is unknown. 736 
 737 
Human functional neuroimaging studies converge with animal studies in identifying 738 
subcortical and cortical brain structures that are involved in the control of eating. Typically, 739 
these studies localize regions that respond differently to food and non-food stimuli, to hunger 740 
and satiety, and in obese and normal-weight women (Morris and Dolan, 2001; Salem and 741 
Dhillo, 2015; Schur et al., 2009; Small and Prescott, 2005; Stoeckel et al., 2008; Wang et al., 742 
2004). Both animal and human receptor expression studies suggest that reproductive 743 
hormones are in a position to affect the function of these regions. For example, in humans, 744 
ESR1 receptors are abundant in the hypothalamus, amygdala, hippocampus, nucleus 745 
accumbens and several cortical regions (Hara et al., 2015). Importantly, this includes 746 
membrane estrogen receptors, which mediate rapid effects on neural activity, as well as 747 
classical nuclear estrogen receptors (Almey et al., 2015). Furthermore, estrogens are 748 
required to maintain dopamine innervation of the striatum, and estrogen and/or progesterone 749 
replacement can rescue ovariectomy-induced reductions in caudate dopamine (Kritzer et al., 750 
2003). Progesterone receptors are also expressed in food-related regions beyond the 751 
hypothalamus, including the caudate (Zhu et al., 2003), amygdala, hippocampus, and frontal 752 
cortex (Brinton et al., 2008). Although the exact role of hormones in many of these regions is 753 
not entirely clear, the widespread distribution of their receptors in areas mediating hedonics, 754 
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motivation and cognition reinforces the notion of their involvement in non-reproductive neural 755 
functions, particularly in the control of normal and dysreguated eating. 756 
 757 
There are sex-related structural differences in brain areas involved in processing food-related 758 
information (Ruigrok et al., 2014); for example, women compared with men express relative 759 
increases in regional grey matter volume or density in frontal cortex, dorsal striatum and right 760 
insula, but relative reductions in ventral striatum, amygdala, hippocampus and left insula. 761 
Sex modulates the functional activation of these regions in a corresponding way. Obese 762 
women show different neural responses to pictures of high-energy food than lean women or 763 
obese men. For example, dorsal striatum activity to high-energy food pictures is particularly 764 
enhanced in obese women (Geliebter et al., 2013; Rothemund et al., 2007). Rodent research 765 
implicates the dorsal striatum in the development of inflexible, habitual control of eating 766 
(Furlong et al., 2014). Accordingly, eating habits may be particularly inflexible in obsese 767 
women. 768 
 769 
Changes in neural responses to food pictures through the menstrual cycle suggest a role of 770 
ovarian homones in processing food-related information. Accordingly, the reduced food 771 
intake in the peri-ovulatory phase of the menstrual cycle is reflected in changes in the 772 
responses of eating-related regions. Specifically, the ventral striatum shows enhanced 773 
activity to high versus low energy-food pictures during the peri-ovulatory compared with the 774 
luteal phase (Frank et al., 2010), in line with the notion of enhanced dopaminergic reward 775 
activity during the peri-ovulatory phase (Dreher et al., 2007; Frank et al., 2010). In a separate 776 
group of subjects, these neural effects were mirrored by reduced appeal of high energy-food 777 
pictures during the peri-ovulatory phase compared with the luteal phase, with unchanged 778 
appeal of low energy-food pictures. Thus, the meal size-limiting effects of estrogens during 779 
the peri-ovulatory phase are mediated by increased ventral striatal responses to high-calorie 780 
food, reflecting increased reward sensitivity induced by higher levels of estrogens. Indeed, 781 
separate research showed a positive correlation between estradiol levels and amphetamine-782 
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induced euphoria in women during the follicular, but not the luteal, phase, suggesting that 783 
estrogens make women more sensitive to (striatal) dopamine (Justice and de Wit, 1999). 784 
These findings converge with reports of reduced reward sensitivity and dopamine release in 785 
obesity and therefore conceptualize increased food intake as an attempt to compensate for 786 
reduced reward value of food (for review, see Val-Laillet et al., 2015). 787 
 788 
Moreover, neural responses to food pictures reflect interactions between prandial state and 789 
menstrual-cycle phase. Specifically, responses to food pictures in the lateral prefrontal cortex 790 
are enhanced in the fed compared with the hungry state during the late follicular (high-791 
estrogen), but not the early follicular (low-estrogen), phase (Alonso-Alonso et al., 2011). 792 
Thus, estrogens may act in the prefrontal cortex to facilitate cognitive control over appetite in 793 
the fed state, i.e., reduce the tendency to “eat in the absence of hunger,” a trait associated 794 
with increased obesity risk (French et al., 2012). In line with this notion, the lateral prefrontal 795 
cortex is less activated after meals in obese women than in lean or formerly obese women 796 
(Le et al., 2007). Furthermore, stronger lateral prefrontal responses to food pictures predict 797 
reduced subsequent energy intake (Cornier et al., 2010), and these responses are smaller in 798 
obese compared with healthy-weight individuals (Batterink et al., 2010). 799 
 800 
Although converging evidence from human neuroimaging studies identifies regions involved 801 
in mediating the influence of ovarian hormones on processing food-related stimuli, there is a 802 
dearth of studies that directly investigate the effects of sex and ovarian hormones on 803 
precisely defined components of neural processing related to eating. Addressing this gap 804 
would involve using real food rather than pictures and paradigms established in the fields of 805 
reinforcement learning, affective neuroscience, and decision neuroscience. For example, it 806 
would be interesting to directly test the effects of estrogens on the neural mechanisms 807 
underlying Pavlovian and goal-directed aspects of eating. One hypothesis would be that 808 
estrogens act in the striatum to make eating behavior flexible and goal-directed.  809 
  810 
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Energy Expenditure (EE)  811 
General aspects of human EE 812 
EE is energy lost in work or heat (urinary nitrogen and glucose losses can also contribute in 813 
pathological situations). Total EE includes REE, the postprandial increase in EE due to 814 
digestive and metabolic handling of ingesta (known as diet-induced thermogenesis (DIT) or 815 
the thermic effect of food), thermoregulatory responses, weight-regulatory EE responses, 816 
and physical-activity EE. REE is also known as resting or basal metabolic rate and is 817 
sometimes subdivided into sleeping and awake, resting components. In moderately active 818 
individuals in a thermoneutral environment, REE usually accounts for ~60-70% of total EE 819 
(Levine, 2004), DIT for ~10-15% (D'Alessio et al., 1988; Reed and Hill, 1996) and physical 820 
activity for the rest. Physical-activity EE can be further subdivided into exercise or sports 821 
activities (including walking for exercise) and non-exercise-activity thermogenesis, which is 822 
the energetic cost of occupational physical activity and incidental daily activities, such as 823 
sitting, talking, standing, fidgeting, etc.  824 
 825 
REE is strongly correlated with FFM (r2 ~0.6-0.7), with no sex difference (Blundell et al., 826 
2010; Johnstone et al., 2005). Individuals with lower REE/FFM values are at increased risk 827 
for weight gain (Ravussin et al., 1988), suggesting that genetic differences in the cellular 828 
components of REE may contribute to individual differences in obesity risk (Konarzewski and 829 
Książek, 2013). About half of REE is due to membrane processes, mainly Na+/K+-ATPase 830 
and UCP-mediated mitochondrial proton leak (Hulbert and Else, 2005). A decline in UCP 831 
activity may explain the decrease in REE with aging (Saito, 2013; St-Onge and Gallagher, 832 
2010) which, as reviewed below, complicates studies of menopausal effects on REE.  833 
 834 
The much lower requirement for physical-activity EE in developed societies is thought to 835 
contribute to the obesity epidemic and to disease risk (Woolf et al., 2008). Physical activity 836 
not only directly increases EE, but also increases REE (Gilliat-Wimberly et al., 2001; Van 837 
Pelt et al., 2001). Physical-activity EE can be expressed as metabolic-energy equivalents 838 
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(MET), the ratio of the rate of EE during the activity and a standard rate, which was originally 839 
based on EE while sitting quietly (ASHRAE, standard 55). Only a few physical laborers or 840 
athletes regularly exceed a daily average level of 2 MET (Levine, 2004). The recommended 841 
minimal level of physical activity for good health in the USA is 500 MET-min/wk (ODPHP, 842 
2016). As moderate-intensity activity, such as walking at ~5 km/h, expends ~3.3 MET and 843 
vigourous-intensity activity, such as jogging at ~8 km/h, expends ~6 MET, this 844 
recommendation can be met by walking for ~150 min/wk or jogging for ~75 min/wk. 845 
Epidemiological data indicate that any level of physical activity reduces adult all-cause 846 
mortality risk and that exceeding the MET recommendation 2-fold or more reduces it by ~30-847 
40% (Arem, Moore, et al., 2015). Only 40% of US Americans, however, meet this 848 
recommendation.  849 
Increased physical-activity EE improves cardiovascular fitness and reduces all-cause 850 
mortality independent of BMI (Barry et al., 2014). Furthermore, higher levels of physical-851 
activity EE predict success in maintaining diet-induced weight loss (Phelan et al., 2006).  852 
Thus, women should be encouraged to increase physical-activity EE, especially after 853 
menopause and in societies in which they tend to be less active (Ford et al., 1991; 854 
Livingstone et al., 2001; Sadarangani et al., 2014). The physiological mechanisms mediating 855 
these mortality effects are not known. Unfortunately, the substantial error in available 856 
methods for measuring habitual physical-activity EE (Arem, Keadle, et al., 2015; Lim et al., 857 
2015) impedes research progress in this area. 858 
 859 
Finally, alterations in total EE contribute to body-weight regulation (Dhurandhar et al., 2015; 860 
Hall et al., 2011; Leibel et al., 1995). If body weight decreases, total EE decreases markedly 861 
more than predicted by the lower body mass, thus strongly resisting further weight loss. This 862 
adaptive reduction in EE is one reason weight loss is so difficult. For example, a reduction in 863 
habitual intake by 200 kcal/d will lead to 19 kg weight loss in 3 y, vs. a predicted weight loss 864 
of 78 kg if there were no adaptation in EE (Hall et al., 2011). The underlying mechansims are 865 
not fully understood. Changes in the amount or efficiency of physical-activity EE (Leibel et 866 
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al., 1995; Levine, 2004; Levine et al., 1999) and in UCP-1 expression in brown-AT (Fromme 867 
and Klingenspor, 2011; Morrison et al., 2014) appear to contribute. 868 
 869 
Roles of ovarian hormones  870 
REE  871 
REE per kg body mass is lower in women due to their higher percent AT, but REE per kg 872 
FFM does not appear to differ between the sexes (Buchholz et al., 2001; Johnstone et al., 873 
2005). This deserves more research, however, with more accurate measurement methods; 874 
in the studies cited, residual variability was ~25% of REE, i.e., ~300-400 kcal/d (Wang et al., 875 
2011). Interestingly, women’s AT is more metabolically active and ~10 fold more variable 876 
than men’s (Buchholz et al., 2001). This is due in part to a 5-fold higher expression of UCP-1 877 
in women’s brown adipocytes (Nookaew et al., 2013).  878 
 879 
REE varies over the menstrual cycle, from a minimum in the early follicular phase to a 880 
maximum ~50-100 kcal/d more in the luteal phase (Day et al., 2005). Administration of a 881 
GnRH antagonist during the mid-luteal phase reduced REE to the early-follicular level, 882 
indicating a role of ovarian hormones (Day et al., 2005). Progestins seem not to be involved 883 
because high-progestin contraceptives have little effect on REE (Pelkman et al., 2001). 884 
Estrogens may be the cause because transdermal estrogen treatment increases REE in 885 
premenopausal women in whom endogenous ovarian hormones are suppressed by GnRH 886 
antagonism for either six days or five months (Day et al., 2005; Melanson et al., 2015; Van 887 
Pelt et al., 2015).  888 
 889 
The effect of menopause on REE has not received much investigation. In one four-year 890 
longitudinal study beginning with regularly cycling women at least 43 years of age, sleeping 891 
REE decreased by 7.9% in the women who became postmenopausal during the study 892 
compared with 5.3% in those who remained premenopausal, but the difference was not 893 
statistically significant (Lovejoy et al., 2008). In a two-week study of postmenopausal women, 894 
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estrogen treatment did not affect REE (Bessesen et al., 2015). Three-month treatment with a 895 
selective estrogen-receptor agonist also failed to increase REE in ovariectomized old-world 896 
monkeys (Sullivan et al., 2012). In contrast, estrogens clearly increase REE in laboratory 897 
rodents (Rogers et al., 2009), and REE is decreased in Esr1 knockout mice of both sexes, 898 
although not in Esr2 knockouts (reviewed in (Mauvais-Jarvis, 2011; Van Pelt et al., 2015)). 899 
 900 
Dietary-induced thermogenesis (DIT) 901 
Studies of reproductive hormonal effects on DIT are contradictory. DIT has been found to 902 
increase, decrease or not to change in the luteal phase of the menstrual cycle compared with 903 
the follicular phase (Li et al., 1999; Melanson et al., 1996; Piers et al., 1995; Tai et al., 1997). 904 
Estrogen treatment did not affect DIT in premenopausal women in whom endogenous 905 
ovarian hormones were suppressed by GnRH antagonism (Melanson et al., 1996). We know 906 
of no studies of DIT across menopause. 907 
 908 
Physical activity EE  909 
Estrogens increase physical acivity in rats, mice and monkeys, but whether this is so in 910 
humans is unknown (Asarian and Geary, 2013). One study found that healthy-weight and 911 
overweight women walked ~1600 more steps/day (~100-200 kcal/d) during the early-follicular 912 
phase compared with the mid-luteal phase (Day et al., 2005). It is interesting to note that 913 
physical-activity EE decreased during the luteal phase, whereas REE increased. Estrogen 914 
treatment did not affect physical-activity EE in premenopausal women in whom endogenous 915 
ovarian hormones were acutely suppressed by GnRH antagonists (Melanson et al., 1996). 916 
Around the age of menopause, physical activity EE tends to decrease substantially, but 917 
similarly in women who become postmenopausal and those who do not (30 and 39%, 918 
respectively) (Lovejoy et al., 2008). Even if menopause is not the cause, the magnitude of 919 
average decrease in physical-activity EE in aging women is clearly clinically relevant (Woolf 920 
et al., 2008).  921 
 922 
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Surprisingly, most studies indicate that acute physical activity results in negative energy 923 
balance, i.e., energy intake either does not change or is reduced following physical activity 924 
EE (Blundell et al., 2015; Deighton et al., 2013; Howe et al., 2014; King et al., 2011). This 925 
was recently confirmed in a study in which participants expended ∼1.3 MET for two 926 
consecutive days with no change in food intake (Douglas et al., 2015). Why food deprivation 927 
leads to compensatory eating in and acute physical activity does not is unknown (Blundell et 928 
al., 2010). Obviously, at some point regular moderate or high intensity physical activitiy EE 929 
must lead to increase energy intake to avoid weight loss, but how this occurs is also 930 
unknown (Stensel, 2010).  931 
 932 
Central mechanisms  933 
REE. Genetic and physiological studies in mice and rats indicate that estrogens acting via 934 
Esr1 in the ventromedial nucleus of the hypothalamus (VMN) increase EE by increasing 935 
hypothalamic sympathetic outflow, resulting in increased brown-AT UCP-1 activity (Martínez 936 
de Morentin et al., 2014; Musatov et al., 2007; Xu et al., 2011). Because the animals were 937 
maintained below thermoneutrality, however, it is difficult to distinguish REE from 938 
thermoregulatory EE. Pronounced species differences also complicate EE research. For 939 
example, glucocorticoids decrease brown-AT UCP-1 activity in mice, but stimulate it in 940 
humans (Ramage et al., 2016). 941 
 942 
Physical activity. Female rats and mice are much more spontaneously active than their male 943 
conspecifics. Estrogens appear to act in at least three brain areas to stimulate physical 944 
activity in mice and rats. First, (Fahrbach et al., 1985) found that estradiol injections into the 945 
medial preoptic area increased physical activity in rats. Second, Musatov et al. (Musatov et 946 
al., 2007) found that knockdown of Esr1 in the VMH reduced physical activity in female rats. 947 
Using complementary site-specific knockout and pharmacogenetic stimulation of Esr1, 948 
Correa et al. (Correa et al., 2015) demonstrated that VMH Esr1 neurons stimulate physical 949 
activity in female, but not male, mice and are a distinct subpopulation not involved in 950 
 35 
controlling eating, brown-AT activation or fertility, as indicated by the maturation of corpora 951 
lutea. Finally, using site-specific Esr1 knockout or knockdown, (Xu et al., 2015) found that 952 
Esr1 neurons in the medial nucleus of the amygdala also control physical activity, but do so 953 
similarly in male and female mice. 954 
 955 
Physical activity-induced increases in EE affect activity of reward regions of the brain in 956 
humans. For example an escalating six month daily treadmill regimen reduced insula 957 
responses to highly valued food pictures (vs. non-food) in overweight and obese subjects in 958 
the fasted state, and this reduction in insula activation correlated with reduction in fat mass 959 
and body weight (Cornier et al., 2012; McFadden et al., 2013). Moreover, after acute sixty 960 
minute exercise, normal-weight subjects showed increased dorsolateral prefrontal activity 961 
and reduced insula, putamen, orbitofrontal, and hippocampal activity to pictures of high 962 
calorie food (vs. non-food) (Crabtree et al., 2014; Evero et al., 2012). These changes could 963 
explain the inhibitory effect of exercise on eating described above. In particular, exercise 964 
downregulates the food-related responses of cortical and subcortical reward regions and 965 
upregulates the responses of prefrontal control regions. However, how ovarian hormones 966 
influence the relation between exercise and central food processing remains largely 967 
unknown.  968 
 969 
DISCUSSION  970 
 971 
Obesity results from a tonically greater energy intake than EE. This simple truth belies the 972 
facts that the controls of eating and EE, the development of obesity, and the cardiometabolic 973 
consequences of the amount and distribution of AT are each multifactorial processes 974 
involving genetic, epigenetic, metabolic, endocrine, psychological, social and cultural factors, 975 
most of which are poorly understood. Because obesity remediation is a worldwide health 976 
challenge and because current strategies for weight reduction, other than bariatric surgery, 977 
have limited efficacy, there is an urgent need for research aimed at developing, first, further 978 
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preventive and therapeutic strategies to achieve and maintain healthy levels of adiposity, and 979 
second, to minimize cardiometabolic and other risks of increased adiposity. Physiological sex 980 
differences are important variables in these processes. This should be clear from the marked 981 
sex differerences in obesity prevalence, especially prevalence of severe obesity (BMI ≥ 35 982 
kg/m2).    983 
 984 
We find that sex-specific physiological mechanisms, especially estrogen-mediated effects, 985 
play significant roles in the development of obesity in women as well as in its 986 
pathophysiological consequences. Table 2 summarizes well established and probable 987 
female-specific obesity-related mechanisms, based on a wide variety of human and animal 988 
research. Estrogens act in the brain, in the AT and in other peripheral sites to affect (1) the 989 
proximal causes of obesity, i.e., relative increases in eating and decreases in EE, (2) the 990 
amount and regional distribution of AT, and (3) AT depot-specific pathophysiological changes 991 
that lead to morbidity. As a result, estrogens contribute both to male-female sex differences 992 
in obesity and obesity co-morbidities and to changes in obesity and obesity co-morbidities 993 
through women’s lives (Figure 5). Therefore, understanding the full impact of AT on 994 
women’s health will require consideration of hormonal status on each of these processes. 995 
Currently astonishingly few data are available that address the normal physiology of these 996 
processes, much less the effects of surgical and hormonal treatments on female overweight 997 
and obesity or the pathophysiology of endocrine disorders with obesity as a frequent co-998 
morbidity. 999 
 1000 
Many of the effects described in Table 2 may appear to be small. For example, changes in 1001 
food intake and EE through the menstrual cycle are on average only a few hundred kcal/d. It 1002 
should be realized, however, that regular small changes in energy balance can lead to 1003 
substantial differences in body weight and therefore be of considerable physiological 1004 
relevance. The best available estimates indicate that an average increase of only 240 kcal/d 1005 
in energy intake over EE is sufficient to produce the mean increase in average body weight 1006 
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that underlies the obesity epidemic in the USA (Hall et al., 2011). Thus, the phenomena 1007 
reviewed here are medically relevant and worthy of increased basic and clinical research.  1008 
 1009 
It is also clear that obesity-related physiological characteristics vary widely across individual 1010 
women. For example, as reviewed above, although most obese women display the female 1011 
typical pattern of relatively more gluteofemoral AT than central AT, some women have male-1012 
typical, central AT distribution (Karpe and Pinnick, 2015). The effects of menstrual cycle on 1013 
flavour preferences also display great inter-subject variability (Bartoshuk et al., 1994; 2006). 1014 
Such variability may arise for many reasons, ranging from psychological, social and cultural 1015 
influences on one side to genetic and epigenetic effects on the other side (Shepard et al., 1016 
2009). Inter-subject variability together with the modest effect sizes mentioned above is a 1017 
great challenge for research and an impediment to translation of research data into clinical 1018 
practice. Research can meet this challenge in a variety of ways. Sample sizes should be 1019 
based on power calculations taking effect size and variability into account. In addition, 1020 
special care is required in sex research to consider subject characteristics, including age, 1021 
race, ethanol use, stress levels or “allostatic load,” psychological traits such as tendencies for 1022 
emotional or binge eating, etc., that can alter the sex-specific influences on AT physiology, 1023 
eating and EE. In such cases, appropriate statistical tools are helpful; for example, the 1024 
multiple-regression analyses described above that parse the separate effects of aging and 1025 
menopause on AT. Finally, researchers should avail themselves of the many methodological 1026 
improvements that can increase the efficiency and meaning of pre-clinical and clinical sex-1027 
related research (Becker et al., 2005; Greenspan et al., 2007; Keitt et al., 2003; McCarthy et 1028 
al., 2012; Rubinow and Schmidt, 2002). 1029 
 1030 
The homogeneity of study groups with respect to reproductive physiology status itself is 1031 
another important issue that often is overlooked, in part because findings in one domain fail 1032 
to reach researchers in other domains. This is one of many reasons that inter-disciplinary 1033 
investigator groups should be facilitated. Thus, post-menopausal study participants should 1034 
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be characterized, menstrual cycles should be evaluated more accurately in both obese and 1035 
non-obese women, and effects of the type and duration of HT, including the interval between 1036 
menopause and beginning HT, should be assessed. In women with surgical menopause, the 1037 
indication for ovariectomy and whether hysterectomy was also done should be considered. In 1038 
addition, as it is likely that indications for gynaecological surgery differ in obese and non-1039 
obese women, due, for example to the higher prevalence of endometrial cancer and 1040 
disturbed bleeding patterns in obese women (Crujeiras and Casanueva, 2015; Madsen et al., 1041 
2013), associations between surgical menopause and adiposity and AT distribution need to 1042 
be explored. A related issue is that reproductive physiology, in particular estrogens, also may 1043 
influence experimental outcomes via “off-target” physiological functions. For example, 1044 
pharmacological data in women may be influenced by differences in the bioactivity of many 1045 
drugs due to sex differences in cytochrome p450 enzyme activity, effects of estrogens on 1046 
hepatic drug metabolism, and effects of estrogens on plasma levels of sex-hormone binding 1047 
globulin and other globulins (Soldin and Mattison, 2009; Spoletini et al., 2012).  1048 
 1049 
We acknowledge weaknesses of the review. We focused on the classical AT depots, 1050 
although excess adiposity is also associated with increased hepatic, intramuscular and 1051 
cardiovascular fat, which are independently associated with cardiometabolic risk and appear 1052 
to be affected by hormonal status in women (Khoudary et al., 2015; Marino and Jornayvaz, 1053 
2015; Oosthuyse and Bosch, 2012). We focused mainly on preclinical whole-body 1054 
mechanistic studies, at the expense of detailed reviews of cell- and tissue-level studies, 1055 
genome-wide gene association studies, and epidemiological studies, despite the many 1056 
plausible mechanistic hypotheses that these suggest. We did not consider pregnancy, 1057 
although postpartum weight gain is an important obesity risk (Gore et al., 2003).  We did not 1058 
consider tissue-specific synthesis of estrogens in the brain or AT or production of neurally 1059 
active estrogen metabolites or other neurosteroids (Azcoitia et al., 2011; Do Rego et al., 1060 
2012; Porcu et al., 2016). 1061 
 1062 
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In conclusion, current human and animal research supports significant roles of ovarian 1063 
hormones, especially estrogens, in the regulation of female AT. These involve influences on 1064 
eating, EE, AT amount, regional AT distribution and the physiological function of adipocytes 1065 
in the various AT depots. In the coming years, improvements in research design and 1066 
analyses and the development of additional powerful methodologies should lead to important 1067 
progress across the range of diverse influences of female physiology on adiposity. Continued 1068 
animal research should better characterize, for example, the site and nature of estrogen 1069 
receptors in the brain that affect eating and EE. Animal research should also lead the way to 1070 
identifying the downstream molecular mechanisms responding to the activation of estrogen 1071 
response elements in the DNA, which contribute the hormone’s effects on gluteofemoral AT 1072 
and on most, if not all, of its neural effects. A pressing issue in this connection is the better 1073 
understanding of the interaction of estrogenic and genetic controls leading to the protective 1074 
cardiometabolic effects of gluteofemoral AT. Similarly, improvements in the design of fMRI 1075 
studies should help specify the neural information-processing mechanisms underlying sex-1076 
related hedonic and cognitive controls of eating. Progress in these and other research 1077 
directions described here should lead to better understanding of female obesity, including 1078 
clinically challenging syndromes such as PCOS and, ultimately, to better strategies to 1079 
maintain and improve women’s health in the face of the obesity epidemic. 1080 
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Table 1. Menopause-associated increases in adiposity, measured with DEXA or CT and 
dissociated from the effect of aging with multiple-regression analysis. 
______________________________________________________________________ 
           Study    Lean Mass  Fat mass  % Fat  
          (kg)                  (kg)  
Menopausal status : Pre- Post-  Pre- Post-  Pre- Post 
Panotopoulos et al. (1996) 43 41*  30 31*  ~ 41 ~ 44* 
Ley et al. (1992)  38±3   38±3  19±6 23±5*    32   36* 
Trémollieres et al. (1996) 36±3   36±3a              18±5 18±5a      32   32a 
                                                          35±3b*                         20±5b*                         35b*    
Phillips et al. (2008)               41   37                  22±1 32±2*             ~ 35      ~ 46 
Svendsen et al. (1995)    ∆ = -4.0*                  ∆ = +3.1*               ∆ =  +5.4±1.6* 
______________________________________________________________________ 
Data are means ± SEM; lean mass does not include bone; ~  indicates estimated from data given. 
Subject characteristics (mean ± SD) were: (Panotopoulos et al., 1996): French women, 26 
premenopausal, aged 43 ± 4 y, BMI 31 ± 3 kg/m2, and 73 postmenopausal, aged 54 ± 4 y, BMI 
31 ± 4 kg/m2; data are sums of arms, trunk and legs, not whole body; variabilities of sums not 
given; Ley et al (Ley et al., 1992): British women, 61 premenopausal, aged 32 ± 6 y, BMI 22 
± 2 kg/m2, and 70 postmenopausal, aged 53 ± 5 y, BMI 24 ± 2 kg/m2; (Trémollieres et al., 
1996): French women, 68 premenopausal, aged 49 ± 3 y, BMI 22 ± 2 kg/m2, a100 younger 
postmenopausal, aged 54 ± 3 y, BMI 22 ± 2 kg/m2, and b37 older postmenopausal, aged 64 ± 
4 y, BMI 23 ± 2 kg/m2; (Phillips et al., 2008): US American women, 58 premenopausal, aged 
39 ± 1 y, BMI 24 ± 1 kg/m2, and 20 postmenopausal, aged 61 ± 2 y, BMI 28 ± 1 kg/m2, not all 
variability or statistics reported; (Svendsen et al., 1995): Swedish women collated by age 
decade; overall n = 407, age range 18-80 y, mean BMI per decade, ~22 - 25 kg/m2.; data are 
estimated menopause effect (∆).  *Significant menopause effect. 
 
 1 
Table 2.  Sex differences and effects of estrogens on adiposity, eating, and EE in women  
 
Adiposity  
  Beginning at puberty, positive energy balance leads to female-typical AT 
distribution, i.e., greater accretion of gluteofemoral subcutaneous AT and less 
accretion of visceral AT.  
 Estrogens and adipocyte genes synergize to produce female-typical AT 
distribution.  
  Loss of estrogens after menopause increases total adiposity and decreases lean 
body mass, and estrogenic HT prevents this. 
  Loss of estrogens after menopause partially reverses female-typical regional AT 
distribution, and estrogenic HT prevents this. 
 
Eating 
   Increasing estrogen secretion through the follicular phase progressively reduces 
daily food intake.  
  Estrogens act on Esr1-expressing neurons in the cmNTS to increase CCK-
mediated satiation; several other meal-control mechanisms may participate. 
   Sex differences in gustatory sensory function affect eating 
  Genetic defects in brain α-MSH–MC4R signalling lead to a more marked 
overeating and obesity syndrome in females than males.  
  Neuroimaging studies indicate that estrogens increase the activity of striatal 
dopaminergic neurons that processing of flavour hedonics. 
  Neuroimaging studies indicate that estrogens increase lateral prefrontal cortex 
processing of cognitive controls inhibiting eating.  
EE 
   Estrogens increase REE during the luteal phase.  
  Estrogens act in several brain sites to increase physical activity EE in rats and 
mice. 
 
Note:  indicates well established effects in humans with proven or likely clinical relevance, 
as reviewed in text;  indicates effects apparent effects in humans with as yet uncertain 
clinical relevance;  indicates effects established in animal research. Abbreviations: α-MSH 
α-melanocyte-stimulating hormone; MC4R, melanocortin 4 receptor. 
 
 
